Vanda falls as US FDA extends review of motion sickness drug

Shares of drugmaker Vanda Pharmaceuticals VNDA.O fall 1.1% at $5.14 premarket

Co says U.S. FDA has requested an extension to complete their review of a partial hold on long-term studies of its experimental motion sickness drug, tradipitant

VNDA says U.S. FDA will now finish its expedited re-examination of the restrictions by December 5, 2025, instead of the original November 26 deadline

FDA has started labeling discussions for tradipitant "New Drug Application"; PDUFA action date stays at Dec. 30 - VNDA

Up to last close, stock up ~11% YTD